1. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
- Author
-
Liu J, Skradis A, Kolar C, Kolath J, Anderson J, Lawson T, Talmadge J, and Gmeiner WH
- Subjects
- Adenocarcinoma enzymology, Adenocarcinoma pathology, Animals, Antimetabolites, Antineoplastic pharmacokinetics, Antimetabolites, Antineoplastic pharmacology, Biotransformation, Body Weight drug effects, Chromatography, High Pressure Liquid, Colorectal Neoplasms enzymology, Colorectal Neoplasms pathology, Drug Resistance, Neoplasm, Enzyme Inhibitors pharmacokinetics, Enzyme Inhibitors pharmacology, Enzyme Inhibitors toxicity, Fibroblasts drug effects, Fibroblasts enzymology, Fluorodeoxyuridylate pharmacokinetics, Fluorodeoxyuridylate pharmacology, Fluorouracil pharmacokinetics, Fluorouracil pharmacology, Half-Life, Humans, Lethal Dose 50, Mice, Mice, Inbred BALB C, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins metabolism, Orotate Phosphoribosyltransferase metabolism, Prodrugs pharmacokinetics, Prodrugs pharmacology, Thymidine Kinase metabolism, Thymidylate Synthase antagonists & inhibitors, Tumor Cells, Cultured drug effects, Antimetabolites, Antineoplastic toxicity, Fluorodeoxyuridylate toxicity, Fluorouracil toxicity, Prodrugs toxicity
- Abstract
The efficacy of treatment with 5-Fluorouracil (5-FU) is limited, in part, by its inefficient conversion to 5-Fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP). We present data indicating that FdUMP[10], designed as a pro-drug for intracellular release of FdUMP, is cytotoxic as a consequence of uptake of the multimeric form. FdUMP[10] is stable in cell culture medium, with more than one-half of the material persisting as multimers of at least six nucleotides after a 48 h incubation at 37 degrees C. FdUMP[10] is more than 400 times more cytotoxic than 5-FU towards human colorectal tumor cells (H630). FdUMP[10] also has decreased toxicity in vivo, with doses as high as 200 mg/kg/day (qdx3) administered to Balb/c mice without morbidity, compared to a maximum tolerated dose of 45 mg/kg/day for 5-FU using the same protocol. FdUMP[10] shows reduced sensitivity to OPRTase- and TK-mediated drug resistance, relative to 5-FU and FdU, respectively, and is much more cytotoxic than 5-FU towards cells that overexpress thymidylate synthase. Thus, FdUMP[10] is less susceptible to resistance mechanisms that limit the clinical utility of 5-FU. The increased cytotoxicity, decreased toxicity in vivo, and reduced sensitivity to drug resistance of FdUMP[10], relative to 5-FU, indicates multimeric FdUMP is potentially valuable as an anti-neoplastic agent, either as a single agent, or in combination with 5-FU.
- Published
- 1999
- Full Text
- View/download PDF